Public Notifications

Search

Search Results

Search Again
Deol, Harpreet Singh (Feb 5, 2020)

  1. Nature of Action: ​The Inquiry Committee of the College of Pharmacist of British Columbia (the “College”) conducted an investigation into the practice of Harpreet Deol (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: February 5, 2020

  3. Name of registrant: Harpreet Singh Deol​

  4. Location of Practice: Abbotsford, BC

  5. Admissions and Acknowledgements:

    Between February 2018 and August 2019, the Registrant took unauthorized medications for his own personal use from the pharmacy for which he was director and pharmacy manager. The medications taken included, but were not limited to, 11,000 tablets and 116,000 millilitres of narcotic drug substances and 200 tablets and 7 vials of controlled drug substances, both of which require an authorized prescription.

    The Registrant did not process or bill these medications on PharmaNet and these medications were reportedly not provided to any other persons. All narcotic and controlled drug inventory was ordered and managed under the Registrant’s credentials and may have contributed to these losses going undetected.

    A College inspection conducted on August 7th, 2019 identified additional deficiencies in the Registrant’s management of the pharmacy and the pharmacy’s overall practice which included, but were not limited to, inaccurate dispensing of Methadone, inadequate/incomplete documentation, a lack of policies and procedures, inadequate record keeping and management of narcotic inventory, and inadequate pharmacy security

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that include (but are not limited to) the following:

    1. To suspend his registration as a pharmacist for a total of 90 days, ending September 9, 2020;

    2. To not be pharmacy manager, director, or officer of a pharmacy for a period of three years from September 10, 2020 to September 9, 2023;
       

    3. To not be a preceptor or supervisor of pharmacy students or international pharmacy graduates for a period of three years from September 10, 2020 to September 9, 2023;

    4. In relation to narcotic and controlled drugs, to not place and receive orders, destroy expired inventory, or have signing authority relating to the ordering of such substances for a period of three years from September 10, 2020 to September 9, 2023;

    5. To complete and successfully pass an ethics course for healthcare professionals;

    6. To complete and successfully pass training courses pertaining to the provision of Opioid Agonist Treatment (OAT) to patients and the management of a community pharmacy; and

    7. To pay a fine of $2,500.

  7. Rationale:

    The Inquiry Committee considered that in this case, in addition to the serious misconduct, the Registrant placed himself and his patients at significant risk of harm when he took unauthorized medications for personal use and continued to practice in the capacity of a pharmacist. His actions were a serious contravention of standards in the Code of Ethics, and compromised the public’s trust in the pharmacy profession as a whole.

    The Inquiry Committee therefore determined that the Registrant required serious remediation and deterrence regarding his conduct. After also considering significant mitigating factors, the Inquiry Committee considered the terms of the Consent Agreement appropriate to protect the public, as well as send a clear message of deterrence to the profession.

Bao, Leanne Hong Le (Jan 31, 2020)

  1. Nature of Action: ​The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Leanne Hong Le Bao (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: January 31, 2020

  3. Name of registrant: Leanne Hong Le Bao

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    The Registrant has admitted and/or acknowledged the following (in part):

    1. The Registrant was in breach of her previous consented undertakings, which can be considered professional misconduct under section 26 of the HPA;
       

    2. The Registrant did not process methadone prescriptions on PharmaNet prior to dispensing on at least 25 occasions, contrary to section 21(1) now section 35(1) of the Pharmacy Operations and Drug Scheduling Act (“PODSA”), Bylaws;

    3. The Registrant did not ensure appropriate documentation and record keeping relating to Methadone Maintenance Treatment practices, contrary to principle 4.1.3 and 2.1.2 of Professional Practice Policy – 66;

    4. As pharmacy manager, the Registrant did not ensure that the pharmacy’s premise was suitable for operation, contrary to section 2(1)(b)(iv) of PODSA prior to April 1, 2018, section 11(2)(c)(d) now section 25(2)(c)(d) of the PODSA, Bylaws and section 8(a) of the Food and Drugs Act. 
       

  6. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee of CPBC, wherein the Registrant consented to the following terms (in part): 

    1. To not be a pharmacy manager until:

      • She has completed Jurisprudence Exam;
      • She has completed “The BC Community Pharmacy Manager Training Program” offered by the British Columbia Pharmacy Association; and
      • She has met with the Deputy Registrar to reflect on her conduct and how she will improve her pharmacy practice going forward.
         
    2. To acknowledge a CPBC follow-up inspection may be conducted within a year; and
       

    3. To pay a $5,000.00 fine.​

  7. Rationale:

    The Registrant consented to undertakings in relation to a previous file. The undertakings in the previous file included the College conducting a follow-up inspection. Upon re-inspection, College investigators observed similar deficiencies, including narcotic counts and reconciliations were not completed, Methadone Maintenance Treatment documentation and record keeping were not appropriately completed, and the Pharmacy premise was not suitable for dispensing. Based on this, the Inquiry Committee determined the Registrant’s practice did not comply with the legislated practice standards and that the Registrant was in breach of her previous Consent Agreement, which can be considered as professional misconduct. The Inquiry Committee considered the Registrant’s conduct to be serious and that the Registrant required remediation and a deterrence in order for her practice to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. 

Wiebe, Shaun Ross (Dec 27, 2019)

Nature of Action: Pursuant to section 35(1)(b) of the Health Professions Act R.S.B.C. 1996, c. 183 (“HPA”), the Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) has ordered a suspension of the registration of registrant Shaun Ross Wiebe pending completion of an investigation, unless he provides medical evidence from an addiction medicine specialist, satisfactory to the College, that he is fit to resume practice, or he successfully applies to the Inquiry Committee to cancel the suspension under section 35(4) of the HPA.

The registrant will not be able to practice pharmacy in the province of British Columbia while his registration is suspended.

Effective Date: December 27, 2019

Reasons: The Inquiry Committee was satisfied that there is a prima facie evidence that the registrant suffers from a substance addiction that renders him unfit to practice at this time. The Inquiry Committee was of the view that the registrant’s continued practice poses a risk to the public, and that this risk cannot be addressed at this time with conditions or limits. Therefore, nothing short of suspension at this time will adequately protect the public. 

Pharmacist Registrant 40 (Nov 24, 2019)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously be suspended for an indefinite period on May 15, 2019. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) and (6) of the Health Professions Act.

May 15, 2019
(November 24, 2019 - Registration reinstated)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 15, 2019. The Agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacy Technician Registrant 3 (Nov 22, 2019)

The Inquiry Committee has reinstated the pharmacy technician registrant’s registration which had previously been suspended for an indefinite period on September 1, 2018. Pursuant to section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacy technician registrant whereby the pharmacy technician registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all recommendations and treatments prescribed or directed by the registrant’s physicians;
     
  2. To comply with every term of a routine medical monitoring program for a minimum of 36 consecutive months;
     
  3. To be restricted from handling, dispensing and packaging narcotics, controlled substances and sedatives, but not to be restricted from to be working in the same area and/or room where medications are stored, supplied and dispensed by other employees; 
     
  4. To be restricted from disposing or dealing with wastage or breakage of or otherwise handle any narcotics, controlled substances and sedatives;
     
  5. To be permanently restricted to working daytime hours with the latest time being 11:00pm on certain days;
     
  6. To ensure all managers and employers, with whom the registrant gains employment, are aware of the registrant’s limits and conditions on the registrant’s registration pursuant to the Agreement;
     
  7. To inform the College of the registrant’s place of employment as a pharmacy technician and report any changes to the location or management within 48 hours of such change; and
     
  8. To comply with the physician’s recommended schedule for a gradual return to work. 
September 1, 2018
(November 22, 2019 - Registration Reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacy technician registrant to suspend her registration as a pharmacy technician for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The registered pharmacy technician registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 14 (Oct 18, 2019)

Pharmacist registrant 14 has satisfied the terms of an Agreement reached with the Inquiry Committee on January 23, 2013. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed by the Inquiry Committee. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act. 

January 23, 2013
(October 18, 2019 – Limits and conditions removed) 

The Inquiry Committee has reinstated pharmacist registrant’s registration which was previously suspended for an indefinite period of time on December 10, 2012. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with pharmacist registrant to reinstate his registration to Full Pharmacist subject to certain limits and conditions, effective January 23, 2013. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

December 24, 2012
(January 23, 2013 – Registration reinstated) 

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further disposition by the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act. 

Pharmacist Registrant 37 (Oct 15, 2019)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on June 25, 2018. Pursuant to section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will adhere to routine medical monitoring program with the institution currently involved in the Registrant’s case and remain on the program for two years;

  2. In the event of any interruption to the agreed monitoring schedule set out by the medical monitoring program, the Registrant will advise the College of the interruption as soon as possible and provide an explanation for the interruption; and

  3. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in the Registrant’s care.  

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purpose of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.

June 25, 2018
(October 15, 2019 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with pharmacist registrant to suspend registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act. 

Pharmacist Registrant 31 (Jul 19, 2019)

Pharmacist registrant 31 has satisfied the terms of an Agreement reached with the Inquiry Committee on August 22, 2017. Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

August 22, 2017
(July 19, 2019 - Limits and conditions removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on March 20, 2017. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will adhere to routine medical monitoring program with the institution currently involved in the Registrant’s case and remain on the monitoring program for three years;

  2. The Registrant will not work alone in a pharmacy, and will, at all times, have another pharmacist or pharmacy technician/assistant/staff on site at all times;

  3. The Registrant will not have any access whatsoever, on or off-duty, to the narcotic safe in any pharmacy;

  4. The Registrant will not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  5. The Registrant will not dispense own medications;

  6. The Registrant shall disclose to the pharmacy manager/or employer the limits and conditions on the Registrant’s license pursuant to the agreement prior to the commencement of new employment at any pharmacy;

  7. The Registrant will ensure that the pharmacy manager and/or employer with whom the Registrant secures employment submits a written statement to the College declaring their awareness of the Registrant’s medical condition and the agreement;

  8. The Registrant will notify the College, in writing or via e-mail, of places of employment as a pharmacist and report any changes to the location of employment within 48 hours of such change. A reportable change to the Registrant’s place of employment contemplates both commencement and termination of employment;

  9. The Registrant will be restricted from acting in the following roles in the Registrant’s practice:

    • Be a manager of a pharmacy;
    • Be a director of a corporation that owns a pharmacy; and
    • Act as a preceptor.

     

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.

March 20, 2017
(AugUst 22, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement by consent with the pharmacist registrant to voluntarily suspend registration as a pharmacist effective March 20, 2017. The agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Tejani, Diamondali Alladin (Jun 20, 2019)

  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Diamondali Alladin Tejani (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183.

  2. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  3. Effective date: June 20, 2019

  4. Name of registrant: Diamondali Alladin Tejani

  5. Location of Practice: Vancouver, BC

  6. Admissions and Acknowledgements:

    Between July 8, 2016 and November 25, 2016, while he was owner, manager and pharmacist, several pharmacy practice deficiencies were identified. The Registrant has admitted and/or acknowledged the following:

    1. Pharmacy staff provided cash incentives in exchange for daily dispense prescriptions;

    2. He knew or should have known that a pharmacist/patient consultation was required for new and refill daily dispense prescriptions;
       

    3. On several occasions, pharmacy staff entered and did not reverse daily dispense prescriptions on PharmaNet when the patient did not attend the pharmacy;

    4. Pharmacy staff dispensed several prescriptions contrary to the prescriber’s instructions (by providing missed doses for a prescription that was required to be daily dispensed); and
       

    5. Pharmacy staff dispensed several prescriptions without prescription labels.

  7. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee of CPBC, wherein the Registrant consented to the following terms (in part):

    1. To suspend his registration as a pharmacist for 180 consecutive days commencing September 18, 2019 to March 15, 2020.

    2. To not be a pharmacy manager, director, owner (direct or indirect), shareholder in a corporation that owns a pharmacy and preceptor for a period of two years from the date that his suspension ends (March 16, 2020 to March 15, 2022);
       

    3. At his own costs, to complete and pass an ethics course for healthcare professionals; and

    4. To pay a $15,000.00 fine.
       

  8. Rationale:

    The Inquiry Committee determined that the totality of the Registrant’s past and present conduct raised serious concerns about his ethical and professional standards in the course of his practice at the pharmacy as a pharmacist, pharmacy manager and owner. The Inquiry Committee determined that his poor standard of practice warranted limits and conditions imposed on his licence, in addition to a fine and a requirement to take an ethics course in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. 

Ladha, Azizabegum (Jun 7, 2019)

  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“the College”) conducted an investigation into the practice of Azizabegum Ladha (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: June 7, 2019

  3. Name of registrant: Azizabegum Ladha 

  4. Location of Practice: Surrey, BC

  5. Admissions and Acknowledgements:

    Between January 2016 and July 2016, the Registrant worked at two different pharmacies, one of which she was the pharmacy manager. During this time, the following pharmacy practice issues and contraventions of legislation occurred, of which she had direct involvement:

    1. She did not provide adequate pharmacist/patient consultations for refill medications;

    2. She dispensed Schedule I medication in a manner that was not authorized in the prescriptions;

    3. She processed inaccurate and non-current transactions on PharmaNet;

    4. She did not review PharmaNet prior to dispensing prescriptions; and

    5. She did not take reasonable steps to confirm the identity of a patient before dispensing medication for this patient.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to the following terms:

    1. To suspend her registration as a pharmacist for a total of 30 consecutive days;

    2. To not be a pharmacy manager and preceptor for a period of 18 months from the date that her suspension ends;
       

    3. To pay a fine in the amount of $5,000.00; and

    4. To successfully complete and pass the “BC Pharmacy Manager Training Program” offered by the British Columbia Pharmacy Association.

  7. Rationale:

    The Inquiry Committee was concerned that the Registrant had previously consented to undertakings and a reprimand related to her pharmacy practice, from which she should have remediated. However, in this current matter she contravened practice standards which could have endangered patient health. The Inquiry Committee therefore considered the totality of the Registrant’s conduct to be serious, and that she required further remediation and deterrence in order to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.

Pages